Skip to main content
. Author manuscript; available in PMC: 2023 Sep 24.
Published in final edited form as: Lancet. 2022 Sep 12;400(10357):1008–1019. doi: 10.1016/S0140-6736(22)01659-2

Figure 1. Flowchart of Study Population.

Figure 1.

aOne patient failed to receive SBRT due to concern for excess toxicity from overlap with the prior radiation field.

bTwo patients received SBRT to the target lesion and were excluded from the objective response rate.

Abbreviations: NIVO: nivolumab, IPI: ipilimumab, SBRT: stereotactic body radiation therapy